Shilpa Medicare Limited ('SML') has entered into a binding agreement with NXITherapeutics AG based out of Basel, Switzerland for development, supply of a New Chemical Entity (NCE).
SHILPAMED · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Shilpa Medicare has signed a binding agreement with Basel-based biotech NXI Therapeutics AG to develop, manufacture, and supply a novel therapy targeting autoimmune and alloimmune disorders. Under the deal, Shilpa will provide end-to-end CMC development, process scale-up, GMP clinical supply, and long-term commercial manufacturing for the NCE, including support for first-in-human clinical studies. The partnership covers early development through commercialization, positioning Shilpa as a full lifecycle partner. Financial terms are not disclosed, but the agreement includes milestone-linked expansion potential and may extend into a multi-year commercial supply relationship. This is described as Shilpa's third major international development and manufacturing contract in recent months, reinforcing its CDMO and biologics growth track.
Positive for the stock — strengthens Shilpa's CDMO revenue visibility, expands its footprint in the fast-growing autoimmune/immunotherapy segment, and signals rising demand from Western biotech clients. No immediate financial impact since terms are confidential, but long-term upside if the NCE progresses to commercial supply.